EGFR and cancer: Directing recombinant single-chain TRAIL molecules to tumor-specific surface antigens using a diabody-based forced dimerization strategy is not limited to the EGFR and together with appropriate apoptosis sensitizing agents may be a powerful approach to efficiently kill a broad range of cancer cells.